<DOC>
	<DOCNO>NCT00551694</DOCNO>
	<brief_summary>The purpose study compare effect single repeat dos GSK256073 placebo HVT subject administrate GSK256073 HMA107787 study</brief_summary>
	<brief_title>A Second Study Determine Effect GSK256073A HVTs</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include history , physical examination , laboratory test , cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator considers find introduce additional risk factor interfere study procedure Healthy adult male females 18 55 year age , inclusive . Female subject must nonchildbearing potential include premenopausal female document ( medical report verification ) hysterectomy double oophorectomy postmenopausal define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL 6 week postsurgical bilateral oophorectomy without hysterectomy , document hysterectomy tubal ligation sufficient Body weight &gt; 50 kg ( 110 pound ) body mass index ( BMI ) 19 31 : Subjects QTc &lt; 450 msec screening ( QTc &lt; 480 msec subject Bundle Branch Block ) . A signed date write informed consent prior admission study The subject able understand comply protocol requirement , instruction protocolstated restriction Any clinically relevant abnormality identify screen medical assessment , laboratory examination ECG Systolic blood pressure &lt; 100 mmHg ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg screen visit History significant cardiac arrhythmia . Active peptic ulcer disease ( PUD ) and/or history PUD Screening test positive H. pylorus screen visit History gout and/or hyperuricemia A serum creatinine concentration reference range History kidney stone PT and/or aPTT reference range History recurrent indigestion , stomach upset diarrhea Liver function test ( LFTs ) creatinine phosphokinase ( CPK ) normal reference range Positive HIV , Hepatitis B surface antigen Hepatitis C antibody within 3 month screen Positive urine drug alcohol screen screen predose Day 1 period History alcohol consumption exceed , average , 7 drinks/week woman 14 drinks/week men ( 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor ) within 6 month first dose study medication positive alcohol test screen History use tobacco nicotine containing product within 6 month screen positive urine cotinine screen Use antimicrobial , proton pump inhibitor bismuth contain medication within 2 week prior test H. pylorus Screening Use prescription ( include hormone replacement therapy ) nonprescription drug vitamin within 7 day 5 halflives ( whichever longer ) prior administration study medication . Use prescription antibiotic within 14 day prior administration study medication . An exception acetaminophen allow dos &lt; 2g/day Use dietary/herbal supplement include ( limited ) St. John 's wort , kava , ephedra ( huang ) , gingko biloba , DHEA , yohimbe , saw palmetto , ginseng red yeast rice within 14 day prior treatment study medication The subject participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication Exposure four new chemical entity within 12 month prior first dose day History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation Consumption grapefruit grapefruit juice within 7 day prior first dose study medication Donation blood excess 500 mL within 56 day prior dose Unwillingness male subject use condom/spermicide , addition female partner use another form contraception , IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation , engage sexual intercourse female partner could become pregnant . This criterion must follow time first dose study medication 84 day last dose study medication Pregnant nursing woman History rare ( yearly less ) flushing , particularly perimenopausal woman A hemoglobin A1c normal reference range and/or fast blood glucose ≥100 mg/dL screen visit History intraocular pathology , include limited retinitis , uveitis , retinal detachment macular edema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>GSK256073A</keyword>
</DOC>